If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a clinical trial page for referral information. For more information on acute leukaemia clinical trials, get in contact with our Haem A team This email address is being protected from spambots. You need JavaScript enabled to view it..
Open and Recruiting Clinical Trials
AMLM28 / ADAPT
Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy
Trial IDACTRN12623000900617Cancer typeAcute myeloid leukaemiaStatusOpen and recruitingWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
ALLIGHT / D9891C00001A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants with Acute Lymphoblastic Leukemia
Trial IDNCT07109219Cancer typeAcute lymphoblastic leukemiaStatusOpen to recruitmentPhasePhase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancerWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
WUC007-03 / T-RRex
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogenic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Trial IDNCT06514794Cancer typeAcute lymphoblastic leukemia / lymphoblastic lymphomaStatusOpen to recruitmentPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer typesWho can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
cAMeLot-2 / 75276617AML3001
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
Trial IDNCT06852222Cancer typeAcute myeloid leukemiaStatusOpen to recruitmentPhasePhase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer typeWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
90189892AML1001
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Trial IDNCT06651229Cancer typeAcute myeloid leukemia myelodysplastic neoplasmsStatusOpen to recruitmentPhasePhase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients Who can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
TCD17796
A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies
Substudy 01: Title: A Phase 1/Phase 2, open-label, multi-center study, assessing the safety, tolerability and the preliminary efficacy of SAR443579 administered in combination with azacitidine + venetoclax in adult participants with CD123 expressing newly diagnosed Acute Myeloid Leukemia (ND-AML) that are ineligible for intensive chemotherapy
Trial IDNCT06508489Cancer typeAcute myeloid leukaemiaStatusOpen and recruitingPhasePhase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancerWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the clinicaltrials.gov.
SENTI-202-101
A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
Trial IDNCT06325748Cancer typeAcute myeloid leukemia and myelodysplastic syndromeStatusRecruitment on holdPhasePhase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patientsWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
AMLM26 / INTERCEPT
Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML: A Multi-arm, Precision-based, Recursive, Platform Trial
Trial ID
ACTRN12621000439842
Cancer type
Acute myeloid leukemia
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
TCD17197
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Trial ID
NCT05086315
Cancer type
Acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodyplasia
Status
Open to recruitment
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
VICTORY
A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
Trial ID
NCT05005299
Cancer type
Acute leukaemia, myelodysplastic syndrome, chronic lymphocytic leukaemia, B-cell non-Hodgkin lymphoma and plasma cell myeloma
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
AMLM22 / IAPC Trial
The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC)
Trial ID
ACTRN12619000280101
Cancer type
Acute myeloid leukemia
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
CYTB323A12101 / YTB-323
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Trial ID
NCT03960840
Cancer type
Diffuse large B-cell lymphoma and adult acute lymphoblastic leukemia
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.
